Evidence map›Paper›PMID 39827855›Full record

ArticleDigestive diseases (Basel, Switzerland)2025

Comparison of Genetic Mutations of Gastric Cancer Diagnosed before or after Helicobacter pylori Eradication and between Differentiated and Undifferentiated Types Using Next-Generation Sequencing.

Masaaki Kodama, Manami Oda, Kazuhiro Mizukami, Ryo Ogawa, Yuka Hirashita, Masahide Fukuda, Kazuhisa Okamoto, Kensuke Fukuda, Takafumi Fuchino, Sotaro Ozaka and 10 more

Abstract readComparative Study
PubMed Full text at PMC Publisher
In one paragraph

Article in Digestive diseases (Basel, Switzerland), 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

20 authors.

Masaaki KodamaDepartment of Advanced Medical Sciences, Faculty of Medicine, Oita University, Oita, Japan.
Manami OdaDivision of Epigenomics, National Cancer Center Research Institute, Tokyo, Japan.
Kazuhiro MizukamiDepartment of Gastroenterology, Faculty of Medicine, Oita University, Oita, Japan.
Ryo OgawaDepartment of Gastroenterology, Faculty of Medicine, Oita University, Oita, Japan.
Yuka HirashitaDepartment of Gastroenterology, Faculty of Medicine, Oita University, Oita, Japan.
Masahide FukudaDepartment of Gastroenterology, Faculty of Medicine, Oita University, Oita, Japan.
Kazuhisa OkamotoDepartment of Gastroenterology, Faculty of Medicine, Oita University, Oita, Japan.
Kensuke FukudaDepartment of Gastroenterology, Faculty of Medicine, Oita University, Oita, Japan.
Takafumi FuchinoDepartment of Gastroenterology, Faculty of Medicine, Oita University, Oita, Japan.
Sotaro OzakaDepartment of Gastroenterology, Faculty of Medicine, Oita University, Oita, Japan.
Tadayoshi OkimotoDepartment of Gastroenterology, Faculty of Medicine, Oita University, Oita, Japan.
Hisanori AbeAbe Gastrointestinal Endoscopic Clinic, Katashima, Oita, Japan.
Kazumi InabaArita Gastrointestinal Hospital, Maki-machi, Oita, Japan.
Masanori TokoroArita Gastrointestinal Hospital, Maki-machi, Oita, Japan.
Keiko AritaArita Gastrointestinal Hospital, Maki-machi, Oita, Japan.
Hidefumi NishikioriOita San-ai Medical Center, Oita, Japan.
Takashi AbeOita Kouseiren Tsurumi Hospital, Tsurumi, Beppu, Japan.
Takayuki NagaiOita Kouseiren Tsurumi Hospital, Tsurumi, Beppu, Japan.
Satoshi YamashitaDivision of Epigenomics, National Cancer Center Research Institute, Tokyo, Japan.
Kazunari MurakamiDepartment of Gastroenterology, Faculty of Medicine, Oita University, Oita, Japan.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

introductionGenetic abnormalities specific to post-Helicobacter pylori eradication gastric cancer (GC), especially those associated with undifferentiated post-eradication GC, are unknown. We conducted next-generation sequencing of GC diagnosed either before or after eradication to investigate the carcinogenesis of post-eradication GC.

methodsFive cases of post-eradication differentiated GC [HP(-)-D group], five cases of H. pylori-positive differentiated GC [HP(+)-D group], four cases of post-eradication undifferentiated GC [HP(-)-U group], and six cases of H. pylori-positive undifferentiated GC [HP(+)-U group] underwent analysis. DNA was extracted from tumor samples, and non-tumor samples of all subjects. Next-generation target sequencing was conducted using the Ion AmpliSeq Library Kit 2.0 with the Ion AmpliSeq Cancer Hotspot Panel v2. Next-generation targeted sequencing results of the cancer part were subtracted from the results of the non-cancer part.

resultsThe HP(-)-D group displayed significantly fewer SNPs in hotspot than the other groups (p < 0.01). Definitive DNA mutations were identified by sequencing of cancerous and non-cancerous tissues. 5 of 20 patients had specific somatic mutations, with different TP53 mutations in the HP(+)-D and HP(-)-U groups, CTNNB1 mutations in the HP(+)-U group, and ATM mutations in the HP(+)-U group, but no mutations in the HP(-)-D group.

conclusionSeveral definite genetic mutations involved in GC were observed. Mutations were less frequent in post-eradication differentiated GC. However, because of small number of cases analyzed to identify carcinogenic differences, further analysis with a large number of cases and with strictly grading GC samples is needed.

introductionGenetic abnormalities specific to post-Helicobacter pylori eradication gastric cancer (GC), especially those associated with undifferentiated post-eradication GC, are unknown. We conducted next-generation sequencing of GC diagnosed either before or after eradication to investigate the carcinogenesis of post-eradication GC.

methodsFive cases of post-eradication differentiated GC [HP(-)-D group], five cases of H. pylori-positive differentiated GC [HP(+)-D group], four cases of post-eradication undifferentiated GC [HP(-)-U group], and six cases of H. pylori-positive undifferentiated GC [HP(+)-U group] underwent analysis. DNA was extracted from tumor samples, and non-tumor samples of all subjects. Next-generation target sequencing was conducted using the Ion AmpliSeq Library Kit 2.0 with the Ion AmpliSeq Cancer Hotspot Panel v2. Next-generation targeted sequencing results of the cancer part were subtracted from the results of the non-cancer part.

resultsThe HP(-)-D group displayed significantly fewer SNPs in hotspot than the other groups (p < 0.01). Definitive DNA mutations were identified by sequencing of cancerous and non-cancerous tissues. 5 of 20 patients had specific somatic mutations, with different TP53 mutations in the HP(+)-D and HP(-)-U groups, CTNNB1 mutations in the HP(+)-U group, and ATM mutations in the HP(+)-U group, but no mutations in the HP(-)-D group.

conclusionSeveral definite genetic mutations involved in GC were observed. Mutations were less frequent in post-eradication differentiated GC. However, because of small number of cases analyzed to identify carcinogenic differences, further analysis with a large number of cases and with strictly grading GC samples is needed.

Indexed as

Helicobacter InfectionsHelicobacter pyloriHigh-Throughput Nucleotide SequencingMutationStomach NeoplasmsAdultAgedCell DifferentiationFemaleHumansMaleMiddle AgedPolymorphism, Single NucleotideEradicationGastric cancerHelicobacter pyloriNext-generation sequencing

Identifiers

PMID39827855
PMCPMC11965840

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.